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Clinical Implications
 The Vitiligo Impact Patient scale is
a well-developed and validated
instrument to measure the impact
of vitiligo.
 Implementation in daily practice
could guide treatment decisions
and concurs with the concept of
personalized medicine.
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Vitiligo: Behind the White Spots
Reinhart Speeckaert1, Jo Lambert1 and Nanja van Geel1The impact of vitiligo is generally believed to be underestimated. Salzes et al.
propose a questionnaire to measure the actual burden of vitiligo. Using a
stepwise approach they constructed and validated this instrument taking into
account the differences between fair and dark skin phototypes. It is a promising
approach that can be implemented on an international scale.
Journal of Investigative Dermatology (2016) 136, 6e7. doi:10.1038/JID.2015.407The impact of a cutaneous disorder on
the quality of life is essential for justi-
fying the need for new treatments and
attracting additional resources for
research. Moreover, from a political
point of view, improvement in the
quality of life is an objective criterion to
determine the cost-effectiveness of
treatment. Some general measurement
tools have been developed for skin
disorders (e.g., dermatology life quality
index, Skindex, etc.). However, as the
spectrum of dermatological diseases is
broad, these more global instruments
are often insufficient (Twiss et al.,
2012).
Vitiligo has a tendency to develop at
visible parts of the body such as the
hands and the face, which are socially
important. Many studies have shown areduced quality of life in patients with
vitiligo, but other studies have not
confirmed a substantial impact of viti-
ligo on life quality. This may be due to
the fact that the generally accepted
dermatological questionnaires such as
the dermatology life quality index and
Skindex-16 lack the sensitivity needed
for a disorder without symptoms such
as pruritus or pain. The first four ques-
tions of the Skindex-16 involve skin
itching, burning, hurting, and irritation
that are not relevant to vitiligo. More-
over, the dermatology life quality index
and Skindex-16 focus in each question
on the complaints the patient had last
week. Although this is appropriate for
patients with skin disorders exhibiting
disease flares and remissions, this is not
ideal for chronic progressive disorders.ital, Ghent, Belgium
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e 136In a number of skin disorders (such as
psoriasis, atopic dermatitis, and acne),
tailored life impact tools have been
developed to describe the disease
burden more accurately.Salzes et al. (2016) report the devel-
opment and validation of a new tool to
assess the burden of vitiligo. In contrast
to most dermatological disorders, viti-
ligo lacks clear inflammatory signs such
as redness, scaling, and itch. This may
lead to the misperception that the
impact of the disease on daily life is
low. It is rather unfortunate that several
different vitiligo impact scores have
been published in the last several years
with only limited international collab-
oration. Krishna et al. (2013) proposed
a vitiligo impact score—subsequently
adapted into a 22-item scale (Vitiligo
Impact Scale-22)—that is quite different
from the Vitiligo Impact Patient scale
(Gupta et al., 2014; Krishna et al.,
2013). However, these studies were
conducted in India, and they reference
issues not relevant to patients in other
parts of the world: concerns about
contagiousness, people who deliber-
ately avoid contact with patients, and
marital issues related to local mis-
perceptions and social stigma toward
dermatological disorders. Lilly et al.
(2013) validated a vitiligo-specific
health-related quality of life instrument,
using a study population with mainly
dark skin (n¼ 90; 65% skin type IVeVI).
The vitiligo-specific health-related
quality of life instrument scale was
recently also validated in Brazilian Por-
tuguese patients with vitiligo (Boza
et al., 2015). This scale resembles the
Vitiligo Impact Patient scale with 12 of
16 questions of the vitiligo-specific
health-related quality of life instrument
COMMENTARYoverlapping with the Vitiligo Impact Pa-
tient scale. As both scales were tested on
geographically diverse populations, this
supports the validity of the approach.
Previously, it has been shown that
several items of the dermatology life
quality index and Skindex are subject to
bias according to cultural differences
(Nijsten et al., 2007), suggesting that
for vitiligo, a global consensus might
best determine the impact score that
should be employed in epidemiological
studies and in clinical trials. Validation
in an international multicenter study
would likely be required.
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TRPV4 in Serotonin-Mediated Itch
Lindsey M. Snyder1,2, Marissa S. Kuzirian1,2 and Sarah E. Ross1,2,3Previous studies have revealed that TRPV1 and TRPA1 function downstream of
many itch receptors,where theymediate inwardcurrent to trigger actionpotentials
in primary afferents. Although other TRP channels, such as TRPV4, are expressed in
primary afferents,whether or not they play an analogous role in itchwaspreviously
unknown. Now, Akiyama et al. provide evidence that TRPV4 is a key mediator of
serotonin-induced itch. This ﬁnding is important because it uncovers an
unanticipated role for TRPV4 in itch, thereby identifying a novel therapeutic target.
Journal of Investigative Dermatology (2016) 136, 7e9. doi:10.1016/j.jid.2015.11.010Clinical relevance of itch
Chronic itch, which is defined as itch
lasting more than 6 weeks, is a prevalent
problem that occurs in approximately
10% of the population (Mollanazaret al., 2015). Chronic itch conditions
negatively affect quality of life, and yet
there are no therapies that are both effi-
cacious and selective for itch. The lackof
effective treatment is partly attributable, Pittsburgh, Pennsylvania, USA; 2The Pittsburgh
tsburgh, Pennsylvania, USA; and 3Department of
ennsylvania, USA
ittsburgh, PA 15213, USA. E-mail: saross@pitt.eduto a poor understanding of the mecha-
nisms that underlie it. Although antihis-
tamines are frequently prescribed as a
treatment for itch, they are typically
ineffective because most types of
chronic itch are not histamine-mediated
(Mollanazar et al., 2015). Unfortunately,
although there are numerous mediators
that can cause itch, the factors that
are responsible in most circumstances
of chronic itch are largely unknown.
One candidate mediator is serotonin
(5-hydroxytryptamine, 5-HT). Human
psychophysical studies have shown that
the application of serotonin into the skin
causes itch (Weisshaar et al., 2004). In
rodents, serotonin is a key component of
mast cells, and it is a potent mediator of
itch. However, until recently, the mech-
anisms through which serotonin causes
itch have remained uncertain.
TRPS as downstream mediators of
itch (pruritogens)
Many pruritogens bind to metabotropic
receptors on primary sensory neurons;
however, these receptors must be
coupled to ionotropic channels via
intracellular signaling pathways to allow
sufficient current influx to generate ac-
tion potentials. Several groups have
shown that the cation channels TRPV1
and TRPA1 are coupled to different
pruritogen receptors and that they are
critical for different forms of itch trans-
mission (Ross, 2011). More specifically,
TRPV1 is required for histaminergic itch,
whereas TRPA1 is required for several
types of nonhistaminergic itch, such as
that induced by chloroquine, BAM8-22,
IL-31, endothelin-1, thymic stromal
lymphopoietin, and bile acids. Until
recently, whether serotonin receptors
were likewise coupled to TRPs remained
unknown.
TRPV4 is a keymediator
of serotonin-induced
itch, thereby identifying
a novel therapeutic
target.Mechanisms of serotonin-induced itch
Understanding serotonin-mediated itch
has been complicated by the fact that
there are numerous serotonin receptors
that are expressed on primary afferents,
as well as on immune mediators thatwww.jidonline.org 7
